4.16 USD
▲+0.19+0.97%
2026-08-03
市值
$154.76M
市盈率
—
EPS
-1.93
股息率
—
52 周区间
3.46 – 5.36
成交量
254.00
Beta
0.67
目标价
11.13
52W 低 3.4652W 高 5.36
价格走势
公司简介
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...